주요 콘텐츠로 건너뛰기
번역 진행 중 — 귀하의 언어 버전을 준비하는 동안 이 콘텐츠가 영어로 표시됩니다.
토론으로 돌아가기

How AI helps scientists design the next generation of medicines

Healthcare
글로벌
July 26, 2026에 시작됨

Designing and developing a new medicine is an expensive, failure-prone scientific challenge. A new drug can take many years to develop, at the cost of a significant investment. And even then, most possible candidates never reach the patient. For biologic medicines, therapies made from engineered proteins rather than synthetic chemistry (which are often used to…

출처 기사

진술 추가 분석 0/5
Need to find a specific claim? Search all statements.
🗳️ Join the conversation
10 투표할 진술 • Your perspective shapes the analysis
📊 Progress to Consensus Analysis Need: 7+ participants, 20+ votes, 3+ votes per statement
Participants 0/7
Statements (10+ recommended) 10/10
Total Votes 0/20
💡 Progress updates live here. Final readiness is confirmed when all three requirements are met.

Your votes count

No account needed — your votes are saved and included in the consensus analysis. Create an account to track your voting history and add statements.

CLAIM 게시자: admin • Jul 26, 2026
AI trained on biased datasets will systematically under-serve medicines for diseases prevalent in low-income countries.

번역 대기 중

Vote options for this statement: agree, disagree, or unsure
💬 토론 보기
Be first to respond
Vote to see results
CLAIM 게시자: admin • Jul 26, 2026
Governments should fund open-source AI drug-design platforms to prevent a monopoly by a few wealthy corporations.

번역 대기 중

Vote options for this statement: agree, disagree, or unsure
💬 토론 보기
Be first to respond
Vote to see results
CLAIM 게시자: admin • Jul 26, 2026
AI's ability to model rare disease genetics will shift investment toward orphan drugs that were previously unprofitable.

번역 대기 중

Vote options for this statement: agree, disagree, or unsure
💬 토론 보기
Be first to respond
Vote to see results
CLAIM 게시자: admin • Jul 26, 2026
AI will enable precision medicine by matching drug candidates to genetic subtypes, making mass-market blockbuster drugs obsolete.

번역 대기 중

Vote options for this statement: agree, disagree, or unsure
💬 토론 보기
Be first to respond
Vote to see results
CLAIM 게시자: admin • Jul 26, 2026
Investment in AI for medicine design should be accompanied by strict regulatory oversight to ensure safety.

번역 대기 중

Vote options for this statement: agree, disagree, or unsure
💬 토론 보기
Be first to respond
Vote to see results
CLAIM 게시자: admin • Jul 26, 2026
AI's strength in predicting molecular properties makes it most valuable for early-stage research, not as a replacement for clinical judgment.

번역 대기 중

Vote options for this statement: agree, disagree, or unsure
💬 토론 보기
Be first to respond
Vote to see results
CLAIM 게시자: admin • Jul 26, 2026
AI-designed drugs are unproven in real patients and regulators must demand identical safety data as traditionally developed medicines.

번역 대기 중

Vote options for this statement: agree, disagree, or unsure
💬 토론 보기
Be first to respond
Vote to see results
CLAIM 게시자: admin • Jul 26, 2026
The complexity of biological systems means that AI cannot fully replace human researchers in drug design.

번역 대기 중

Vote options for this statement: agree, disagree, or unsure
💬 토론 보기
Be first to respond
Vote to see results
CLAIM 게시자: admin • Jul 26, 2026
Patent law must evolve to credit both human researchers and AI systems fairly, or incentives for human innovation will collapse.

번역 대기 중

Vote options for this statement: agree, disagree, or unsure
💬 토론 보기
Be first to respond
Vote to see results
CLAIM 게시자: admin • Jul 26, 2026
Whether or not AI accelerates discovery, drug pricing must remain decoupled from development speed to ensure affordability.

번역 대기 중

Vote options for this statement: agree, disagree, or unsure
💬 토론 보기
Be first to respond
Vote to see results

💡 How This Works

  • • Add Statements: Post claims or questions (10-500 characters)
  • • Vote: Agree, Disagree, or Unsure on each statement
  • • Respond: Add detailed pro/con responses with evidence
  • • Consensus: After enough participation, analysis reveals opinion groups and areas of agreement

Society Speaks is open and independent. Your support keeps civic discussion free from advertising and commercial influence.

Support us